Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab in Japanese Patients with Episodic Migraine
jRCT2080223373Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of galcanezumab in episodic migraine (3 arms), sponsored by Eli Lilly and Company. Started Nov 2016; status: completed.
02
Drugs
galcanezumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on jRCT2080223373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223373.